Cantor Fitzgerald Increases Earnings Estimates for Elutia

Elutia Inc. (NASDAQ:ELUT) – Analysts at Cantor Fitzgerald raised their FY2025 EPS estimates for Elutia in a research report issued on Monday, May 12th. Cantor Fitzgerald analyst R. Osborn now expects that the company will post earnings of ($0.65) per share for the year, up from their previous forecast of ($0.75). Cantor Fitzgerald currently has a “Overweight” rating and a $8.00 target price on the stock. The consensus estimate for Elutia’s current full-year earnings is ($1.74) per share.

Separately, Lake Street Capital reduced their price objective on shares of Elutia from $10.00 to $8.00 and set a “buy” rating for the company in a research note on Friday, May 9th.

Elutia Stock Up 1.2%

Shares of NASDAQ ELUT opened at $1.74 on Wednesday. Elutia has a 52 week low of $1.68 and a 52 week high of $5.24. The firm has a 50-day moving average price of $2.44 and a 200 day moving average price of $3.15. The stock has a market capitalization of $70.88 million, a price-to-earnings ratio of -0.67 and a beta of 0.97.

Elutia (NASDAQ:ELUT) last issued its earnings results on Thursday, May 8th. The company reported ($0.21) earnings per share for the quarter, missing the consensus estimate of ($0.20) by ($0.01). The firm had revenue of $6.03 million for the quarter, compared to analyst estimates of $6.65 million.

Hedge Funds Weigh In On Elutia

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in ELUT. OMERS ADMINISTRATION Corp acquired a new position in Elutia during the first quarter worth about $28,000. Arcus Capital Partners LLC acquired a new position in Elutia during the first quarter worth about $51,000. Northern Trust Corp raised its position in Elutia by 30.0% during the fourth quarter. Northern Trust Corp now owns 17,957 shares of the company’s stock worth $67,000 after acquiring an additional 4,148 shares during the last quarter. Citadel Advisors LLC acquired a new position in Elutia during the fourth quarter worth about $84,000. Finally, Millennium Management LLC raised its position in shares of Elutia by 16.4% in the fourth quarter. Millennium Management LLC now owns 45,217 shares of the company’s stock valued at $169,000 after buying an additional 6,386 shares during the last quarter. Institutional investors and hedge funds own 74.03% of the company’s stock.

Elutia Company Profile

Elutia Inc, a commercial-stage company, develops and commercializes drug-eluting biologics products for neurostimulation, wound care, and breast reconstruction in the United States. The company operates in three segments: Device Protection; Women's Health; and Cardiovascular. It offers CanGaroo Envelope, which is used to accommodate cardiac implantable electronic devices, such as pacemakers and internal defibrillators.